Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study

被引:4
|
作者
Khodashahi, Rozita [1 ]
Naderi, Hamid Reza [1 ]
Sedaghat, Alireza [2 ]
Allahyari, Abolghasem [3 ]
Sarjamee, Soroush [4 ]
Eshaghi, Soudabe [1 ]
Fazeli, Farzaneh [5 ]
Hoseini, Benyamin [6 ]
Dadgarmoghaddam, Maliheh [7 ]
Khodashahi, Mandana [8 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Dept Infect Dis & Trop Med, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Fac Med, Lung Dis Res Ctr, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Fac Med, Dept Internal Med, Mashhad, Razavi Khorasan, Iran
[4] Mashhad Univ Med Sci, Fac Med, Dept Emergency Med, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Fac Med, Dept Crit Care, Mashhad, Razavi Khorasan, Iran
[6] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Razavi Khorasan, Iran
[7] Mashhad Univ Med Sci, Fac Med, Community Med Dept, Mashhad, Razavi Khorasan, Iran
[8] Mashhad Univ Med Sci, Fac Med, Rheumat Dis Res Ctr, Mashhad, Razavi Khorasan, Iran
来源
ARCHIVES OF CLINICAL INFECTIOUS DISEASES | 2021年 / 16卷 / 01期
关键词
COVID-19; Intravenous Immunoglobulin; Intubation; Immune Systems; REGULATORY T-CELLS; SUBCUTANEOUS IMMUNOGLOBULIN; THERAPY; AUTOIMMUNE; NEUTRALIZATION; EFFICACY; DISEASE; IVIG;
D O I
10.5812/archcid.108068
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: It seems that the risk of developing complications associated with coronavirus disease 2019 (COVID-19) is higher among individuals with weakened immune systems. Objectives: Therefore, this study was carried out to determine the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of patients not entering the intubation phase compared to those entering the intubation phase. Methods: This descriptive case-control study was performed on 26 patients with COVID-19 referring to Imam Reza hospital in Mash-had, Iran, in March 2020. For subjects with COVID-19 not responding to the standard three-drug protocol (i.e., ribavirin, hydroxychloroquine, and lopinavir/ritonavir), three doses of IVIG (0.4 g/kg/day) were added to the protocol. The patients were divided into two groups of subjects not entering the intubation phase and those entering the intubation phase and compared in terms of different variables. Results: The comparison of laboratory findings showed a significant difference before and after receiving IVIG regarding oxygen saturation (P < 0.005), white blood cell (P = 0.001), hemoglobin level (P = 0.0002), lymphocyte count (P = 0.03), and C-reactive protein (P = 0.001). In general, 53.8% and 46.2% of the patients were discharged and expired, respectively. All the subjects not entering the intubation phase were recovered; nevertheless, only one case entering the intubation phase was recovered, and 92.3% of the patients expired. A significant difference was observed between the patients not entering the intubation phase and those entering the intubation phase in terms of mortality (chi(2) = 22.28; P < 0.005). Conclusions: In summary, the obtained results of the current study confirmed the therapeutic effects of IVIG on patients with COVID-19. Moreover, better treatment results, shorter hospital stay, and lower mortality rates were observed among COVID-19 patients who did not enter the intubation phase in comparison with those entering the intubation phase.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Intravenous immunoglobulin and treatment in COVID-19 patients: case series
    Mohtadi, Negar
    Ghaysouri, Abas
    Nazar, Ali
    Feizia, Jalil
    Tavan, Hamed
    REVIEWS AND RESEARCH IN MEDICAL MICROBIOLOGY, 2022, 33 (02): : 117 - 120
  • [2] Treatment of a case of COVID-19 by intravenous immunoglobulin
    Colak, Mustafa
    Kalemci, Serdar
    Sarihan, Aydin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 24 : 106 - 107
  • [3] Mucormycosis in COVID-19 Patients: A Case-Control Study
    Pandit, Awadh Kishor
    Tangri, Poorvi
    Misra, Shubham
    Srivastava, Madakasira Vasantha Padma
    Bhatnagar, Sushma
    Thakar, Alok
    Sikka, Kapil
    Panda, Smriti
    Vishnu, Venugopalan Y.
    Singh, Rajesh Kumar
    Das, Animesh
    Radhakrishnan, Divya M.
    Srivastava, Achal Kumar
    Subramaniam, Rajeshwari
    Trikha, Anjan
    Agarwal, Ayush
    Rajan, Roopa
    Upadhyay, Vibhor
    Parikipandla, Sathish
    Singh, Anup
    Kairo, Arvind
    MICROORGANISMS, 2022, 10 (06)
  • [4] Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study
    Hou, Haifeng
    Yang, Huan
    Liu, Pengcheng
    Huang, Changwu
    Wang, Meng
    Li, Yuejin
    Zhu, Mingsong
    Wang, Jing
    Xu, Yuan
    Wang, Youxin
    Ma, Qingwei
    Li, Dong
    Liao, Pu
    Wang, Wei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study
    Liu, Jiao
    Chen, Yizhu
    Li, Ranran
    Wu, Zhixiong
    Xu, Qianghong
    Li, Zhongyi
    Annane, Djillali
    Feng, Huibin
    Huang, Sisi
    Guo, Jun
    Zhang, Lidi
    Ye, Xiaofei
    Zhu, Wei
    Du, Hangxiang
    Liu, Yong'an
    Wang, Tao
    Chen, Limin
    Wen, Zhenliang
    Teboul, Jean-Louis
    Chen, Dechang
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1488 - 1493
  • [6] Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study
    Boglione, Lucio
    Dodaro, Valentina
    Meli, Giulia
    Rostagno, Roberto
    Poletti, Federica
    Moglia, Roberta
    Bianchi, Bianca
    Esposito, Maria
    Borre, Silvio
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (08) : 3653 - 3660
  • [7] Xuebijing injection in the treatment of COVID-19: a retrospective case-control study
    Guo, Hu
    Zheng, Jiangyuan
    Huang, Gu
    Xiang, Yi
    Lang, Chunhui
    Li, Boqun
    Huang, Daoqiu
    Sun, Qiuyan
    Luo, Yaling
    Zhang, Yulian
    Huang, Liang
    Fang, Wei
    Zheng, Yu
    Wan, Suxin
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (05) : 3235 - 3248
  • [8] Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series
    Mohtadi, Negar
    Ghaysouri, Abas
    Shirazi, Samira
    Ansari, Sara
    Shafiee, Elham
    Bastani, Elham
    Kokhazadeh, Taleb
    Tavan, Hamed
    VIROLOGY, 2020, 548 : 1 - 5
  • [9] Dermatologic comorbidities of the patients with severe COVID-19: A case-control study
    Kutlu, Omer
    ogut, Neslihan Demirel
    Erbagci, Ece
    Metin, Ahmet
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [10] COVID-19 hospitalized patients and oral changes: a case-control study
    Ferreira, Marceli Dias
    Lopez, Lourdes Zeballos
    da Silva, Fernanda Pereira
    Mileo, Fernanda Couto
    Bortoluzzi, Marcelo Carlos
    dos Santos, Fabio Andre
    CLINICAL ORAL INVESTIGATIONS, 2023, 27 (08) : 4481 - 4491